

Estimated Frequency of Antiphospholipid Antibodies in Stroke, Myocardial Infarction, and Deep Vein Thrombosis Literature

Arthritis Care and Research

65, 1869-1873

DOI: [10.1002/acr.22066](https://doi.org/10.1002/acr.22066)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Antiphospholipid Antibody Syndrome. , 0, , 305-316.		0
2	Top 10 Clinical Research Developments in Antiphospholipid Syndrome. Current Rheumatology Reports, 2013, 15, 367.	4.7	4
3	Update on the current recommendations and outcomes in pregnant women with antiphospholipid syndrome. Expert Review of Clinical Immunology, 2014, 10, 1505-1517.	3.0	25
4	Revisiting the Molecular Mechanism of Neurological Manifestations in Antiphospholipid Syndrome: Beyond Vascular Damage. Journal of Immunology Research, 2014, 2014, 1-9.	2.2	35
5	Management of Recurrent Thrombosis in Antiphospholipid Syndrome. Current Rheumatology Reports, 2014, 16, 405.	4.7	33
6	Pregnancy Morbidity in Antiphospholipid Syndrome: What Is the Impact of Treatment?. Current Rheumatology Reports, 2014, 16, 403.	4.7	38
7	14th International Congress on Antiphospholipid Antibodies Task Force Report on Obstetric Antiphospholipid Syndrome. Autoimmunity Reviews, 2014, 13, 795-813.	5.8	161
8	Diagnosis and classification of the antiphospholipid syndrome. Journal of Autoimmunity, 2014, 48-49, 20-25.	6.5	238
9	Unrealistic Estimation of Population Prevalence of Antiphospholipid Antibody-Related Pregnancy Loss: Comment on the Article by Andreoli et al. Arthritis Care and Research, 2014, 66, 966-966.	3.4	2
10	Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome. Journal of Thrombosis and Haemostasis, 2015, 13, 1264-1273.	3.8	55
11	Diagnosis and management of non-criteria obstetric antiphospholipid syndrome. Thrombosis and Haemostasis, 2015, 113, 13-19.	3.4	81
12	Anti-Phosphatidylserine/Prothrombin Antibodies Are Associated with Adverse Pregnancy Outcomes. Journal of Immunology Research, 2015, 2015, 1-8.	2.2	39
13	Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management- An Insight into Future Approaches. Journal of Immunology Research, 2015, 2015, 1-20.	2.2	48
15	Secondary Antiphospholipid Syndrome. Rare Diseases of the Immune System, 2015, , 233-248.	0.1	3
16	State of the art: Reproduction and pregnancy in rheumatic diseases. Autoimmunity Reviews, 2015, 14, 376-386.	5.8	169
17	The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review. Annals of the Rheumatic Diseases, 2015, 74, 2028-2033.	0.9	124
18	The association between antiphospholipid antibodies and pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Lupus, 2015, 24, 980-984.	1.6	52
19	Lupus Anticoagulants and Anticardiolipin Antibodies in Indian Women with Spontaneous, Recurrent Fetal Loss. Indian Journal of Hematology and Blood Transfusion, 2015, 31, 281-285.	0.6	1

#	ARTICLE	IF	CITATIONS
20	The Journey of Antiphospholipid Antibodies From Cellular Activation to Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , 2015, 17, 16.	4.7	24
21	Obstetric Antiphospholipid Syndrome: Lobsters Only? Or Should We Also Look for Selected Red Herrings?. <i>Journal of Rheumatology</i> , 2015, 42, 158-160.	2.0	12
22	Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE. <i>Lupus</i> , 2015, 24, 1087-1094.	1.6	70
23	Antiphospholipid syndrome: an update. <i>European Journal of Clinical Investigation</i> , 2015, 45, 653-662.	3.4	37
24	Prevalence of antiphospholipid antibodies and risk of subsequent adverse obstetric outcomes in women with prior pregnancy loss. <i>Journal of Reproductive Immunology</i> , 2015, 107, 59-63.	1.9	28
25	LMWH to prevent placenta-mediated pregnancy complications: an update. <i>British Journal of Haematology</i> , 2015, 168, 619-638.	2.5	33
26	Imaging of activated complement using ultrasmall superparamagnetic iron oxide particles (USPIO) - conjugated vectors: an in vivo in utero non-invasive method to predict placental insufficiency and abnormal fetal brain development. <i>Molecular Psychiatry</i> , 2015, 20, 1017-1026.	7.9	31
27	Antiphospholipid Antibodies: From General Concepts to Its Relation with Malignancies. <i>Antibodies</i> , 2016, 5, 18.	2.5	12
28	Antiphospholipid antibodies and the risk of severe and non-severe pre-eclampsia: the NOHA case-control study. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 675-684.	3.8	24
29	Enfermedades autoinmunes sistémicas en atención primaria. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2016, 23, 513-527.	0.0	0
30	Prevalence of thrombophilic disorders in takotsubo patients: the (Thrombophilia in Takotsubo) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 3	3.3	15
31	Thrombotic Primary Antiphospholipid Syndrome: the profile of antibody positivity in patients from North India. <i>International Journal of Rheumatic Diseases</i> , 2016, 19, 903-912.	1.9	9
32	Renal involvement in primary antiphospholipid syndrome. <i>Journal of Nephrology</i> , 2016, 29, 507-515.	2.0	10
34	Current status and future prospects for the treatment of antiphospholipid syndrome. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 927-935.	3.0	8
35	Antiphospholipid Antibodies and the Risk of Stroke in Urban and Rural Tanzania. <i>Stroke</i> , 2016, 47, 2589-2595.	2.0	12
36	Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. <i>Lancet Haematology</i> , 2016, 3, e426-e436.	4.6	322
37	AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION): 5-Year Update. <i>Current Rheumatology Reports</i> , 2016, 18, 64.	4.7	12
38	Thrombotic risk assessment in antiphospholipid syndrome: the role of new antibody specificities and thrombin generation assay. <i>Clinical and Molecular Allergy</i> , 2016, 14, 6.	1.8	37

#	ARTICLE	IF	CITATIONS
39	Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature. <i>Current Rheumatology Reports</i> , 2016, 18, 74.	4.7	76
40	Role of Novel Oral Anticoagulants in the Treatment of Antiphospholipid Syndrome. <i>Hospital Pharmacy</i> , 2016, 51, 759-767.	1.0	8
42	The challenges of lupus anticoagulants. <i>Expert Review of Hematology</i> , 2016, 9, 389-400.	2.2	31
43	Hematologic Disorders and Stroke. , 2016, , 680-694.e5.		1
44	Cardiac involvement in antiphospholipid syndrome: The diagnostic role of noninvasive cardiac imaging. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 611-616.	3.4	24
45	The antiphospholipid syndrome: from pathophysiology to treatment. <i>Clinical and Experimental Medicine</i> , 2017, 17, 257-267.	3.6	84
46	Obstetric Manifestations of the Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, 12, 107-120.	0.1	0
47	Treatment of Pregnancy Complications in Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, , 257-279.	0.1	0
48	S�ndrome antifosfol�pido. <i>Medicine</i> , 2017, 12, 1551-1559.	0.0	0
49	Antiphospholipid syndrome. <i>Thrombosis Research</i> , 2017, 151, S43-S47.	1.7	195
50	Antiphospholipid antibodies and the risk of pregnancy complications. <i>Thrombosis Research</i> , 2017, 151, S34-S37.	1.7	12
51	Reduction of annexin A5 anticoagulant ratio identifies antiphospholipid antibody�positive patients with adverse clinical outcomes. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1412-1421.	3.8	12
52	Lupus anticoagulant �� hypoprothrombinemia syndrome. <i>Blood Coagulation and Fibrinolysis</i> , 2017, 28, 416-418.	1.0	13
53	Antiphospholipid syndrome: an update for clinicians and scientists. <i>Current Opinion in Rheumatology</i> , 2017, 29, 458-466.	4.3	18
54	Pathogenesis and management of antiphospholipid syndrome. <i>British Journal of Haematology</i> , 2017, 178, 181-195.	2.5	80
55	The adjusted Global Antiphospholipid Syndrome Score (aGAPSS) for risk stratification in young APS patients with acute myocardial infarction. <i>International Journal of Cardiology</i> , 2017, 240, 72-77.	1.7	48
56	Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies. <i>The Cochrane Library</i> , 0, , .	2.8	3
57	Epidemiology of the Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, 12, 17-30.	0.1	17

#	ARTICLE	IF	CITATIONS
58	Detection of lupus anticoagulant in the era of direct oral anticoagulants. <i>Autoimmunity Reviews</i> , 2017, 16, 173-178.	5.8	71
59	Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome. <i>The Cochrane Library</i> , 2017, 10, CD012169.	2.8	19
60	Thrombin activatable fibrinolysis inhibitor (TAFI) – A possible link between coagulation and complement activation in the antiphospholipid syndrome (APS). <i>Thrombosis Research</i> , 2017, 158, 168-173.	1.7	14
61	Drug therapy in anticoagulation: which drug for which patient?. <i>Clinical Medicine</i> , 2017, 17, 233-244.	1.9	9
62	Antiphosphatidylserine/prothrombin antibodies as biomarkers to identify severe primary antiphospholipid syndrome. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 890-898.	2.3	49
63	Recurrent pregnancy loss: current perspectives. <i>International Journal of Women's Health</i> , 2017, Volume 9, 331-345.	2.6	272
64	Anti-phospholipid Syndrome. , 2017, , 1389-1399.		2
66	Antiphospholipid Antibody Syndrome. , 2017, , 590-594.		1
67	Use of direct oral anticoagulants in antiphospholipid syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1028-1039.	3.8	42
68	The treatment of anti-phospholipid syndrome: A comprehensive clinical approach. <i>Journal of Autoimmunity</i> , 2018, 90, 1-27.	6.5	60
69	Extra-criteria manifestations of antiphospholipid syndrome: Risk assessment and management. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 117-120.	3.4	42
70	Antiphospholipid syndrome. <i>Nature Reviews Disease Primers</i> , 2018, 4, 17103.	30.5	233
72	Effectiveness of high-dose i.v. immunoglobulin therapy for pregnant women with aspirin- and heparin-resistant secondary antiphospholipid syndrome. <i>Reproductive Medicine and Biology</i> , 2018, 17, 149-154.	2.4	0
73	Update on Antiphospholipid Syndrome: Ten Topics in 2017. <i>Current Rheumatology Reports</i> , 2018, 20, 15.	4.7	22
74	Maternal Thrombophilia and Recurrent Miscarriage – Is There Evidence That Heparin is Indicated as Prophylaxis against Recurrence?. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 274-282.	1.8	18
75	Heart-Shaped Bilateral Medullary Pyramidal Infarction as a Pathognomonic Finding of Anterior Spinal Artery Occlusion. <i>Neurocritical Care</i> , 2018, 28, 388-394.	2.4	3
76	Antiphospholipid antibodies enhance rat neonatal cardiomyocyte apoptosis in an in vitro hypoxia/reoxygenation injury model via p38 MAPK. <i>Cell Death and Disease</i> , 2018, 8, e2549-e2549.	6.3	17
77	Direct Oral Anticoagulants for Thromboprophylaxis in Patients with Antiphospholipid Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 427-438.	2.7	13

#	ARTICLE	IF	CITATIONS
78	Una reflexión sobre el anticoagulante fármaco: cómo lo definimos, determinamos e interpretamos. <i>Reumatología Clínica</i> , 2018, 14, 120-122.	0.5	0
79	Direct Oral Anticoagulant Use in Atypical Thrombosis-Related Conditions. <i>Annals of Pharmacotherapy</i> , 2018, 52, 185-197.	1.9	3
80	Association of silent infarcts in sickle cell anemia with decreased annexin A5 resistance. <i>Blood Cells, Molecules, and Diseases</i> , 2018, 69, 53-56.	1.4	1
81	Impact of Classical Risk Factors for Arterial or Venous Thrombosis in Patients With Antiphospholipid Syndrome. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 834-840.	1.7	7
82	Low molecular weight heparin and aspirin exacerbate human endometrial endothelial cell responses to antiphospholipid antibodies. <i>American Journal of Reproductive Immunology</i> , 2018, 79, e12785.	1.2	17
83	PEGylated Domain I of Beta-2-Glycoprotein I Inhibits the Binding, Coagulopathic, and Thrombogenic Properties of IgG From Patients With the Antiphospholipid Syndrome. <i>Frontiers in Immunology</i> , 2018, 9, 2413.	4.8	14
85	Antiphospholipid Syndrome and the Neurologist: From Pathogenesis to Therapy. <i>Frontiers in Neurology</i> , 2018, 9, 1001.	2.4	61
86	Severe Preeclampsia, Antiphospholipid Syndrome, and Ulnar Artery Thrombosis in a Teenage Pregnancy: A Rare Association. <i>Case Reports in Obstetrics and Gynecology</i> , 2018, 2018, 1-4.	0.3	2
87	The anti-thrombotic effects of vitamin D and their possible relationship with antiphospholipid syndrome. <i>Lupus</i> , 2018, 27, 2181-2189.	1.6	19
89	Obstetric antiphospholipid syndrome. <i>Lupus Science and Medicine</i> , 2018, 5, e000197.	2.7	42
90	Antiphospholipid Antibodies to Domain I of Beta-2-Glycoprotein I Show Different Subclass Predominance in Comparison to Antibodies to Whole Beta-2-glycoprotein I. <i>Frontiers in Immunology</i> , 2018, 9, 2244.	4.8	11
91	Primary Thrombosis Prophylaxis in Persistently Antiphospholipid Antibody-Positive Individuals: Where Do We Stand in 2018?. <i>Current Rheumatology Reports</i> , 2018, 20, 66.	4.7	16
92	The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: A comprehensive review. <i>Journal of Autoimmunity</i> , 2018, 92, 1-11.	6.5	143
93	Diagnosis and Management of the Antiphospholipid Syndrome. <i>New England Journal of Medicine</i> , 2018, 378, 2010-2021.	27.0	503
94	A Reflection on How We Define, Determine and Interpret the Finding of Lupus Anticoagulant. <i>Reumatología Clínica (English Edition)</i> , 2018, 14, 120-122.	0.3	0
95	Recent Developments in Antiphospholipid Antibodies and the Antiphospholipid Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 417-418.	2.7	3
97	Hypercoagulable states in arterial and venous thrombosis: When, how, and who to test?. <i>Vascular Medicine</i> , 2018, 23, 388-399.	1.5	24
98	Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies. <i>The Cochrane Library</i> , 2018, 2018, CD012534.	2.8	28

#	ARTICLE	IF	CITATIONS
99	Obstetric Anti-phospholipid Syndrome: State of the Art. <i>Current Rheumatology Reports</i> , 2018, 20, 59.	4.7	12
100	Everything the clinician needs to know about evidence-based anticoagulation in pregnancy. <i>Blood Reviews</i> , 2019, 33, 82-97.	5.7	33
101	Stroke and antiphospholipid syndrome—antiphospholipid antibodies are a risk factor for an ischemic cerebrovascular event. <i>Clinical Rheumatology</i> , 2019, 38, 379-384.	2.2	19
102	Antiphospholipid syndrome: a clinical review. <i>Medical Journal of Australia</i> , 2019, 211, 184-188.	1.7	16
103	The Role of Transcranial Doppler Monitoring in Patients with Multi-Territory Acute Embolic Strokes: A Review. <i>Journal of Neuroimaging</i> , 2019, 29, 309-322.	2.0	15
104	Lung Disease in Antiphospholipid Syndrome. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2019, 40, 278-294.	2.1	10
106	The Epidemiology of Antiphospholipid Syndrome: A Population-Based Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 1545-1552.	5.6	172
107	High detection rates of antithrombin deficiency and antiphospholipid syndrome in outpatients aged over 50 years using the standardized protocol for thrombophilia screening. <i>Thrombosis Research</i> , 2019, 176, 67-73.	1.7	8
108	What's new in obstetric antiphospholipid syndrome. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 421-425.	2.5	8
109	Pathogenesis of Antiphospholipid Antibody Syndrome. , 2019, , 324-337.		3
110	Clinical Aspects of Antiphospholipid Syndrome. , 2019, , 532-542.		0
111	Role of NOD2 in antiphospholipid antibody-induced and bacterial MDP amplification of trophoblast inflammation. <i>Journal of Autoimmunity</i> , 2019, 98, 103-112.	6.5	12
112	Recurrent venous thromboembolism after discontinuation of rivaroxaban therapy in a patient with antiphospholipid syndrome. <i>BMJ Case Reports</i> , 2019, 12, bcr-2018-227663.	0.5	0
113	Antiphospholipid Antibodies in Patients With Myocardial Infarction. <i>Annals of Internal Medicine</i> , 2019, 170, 277.	3.9	17
114	Anti-Î2-glycoprotein I antibody with DNA binding activity enters living monocytes via cell surface DNA and induces tissue factor expression. <i>Clinical and Experimental Immunology</i> , 2019, 195, 167-178.	2.6	15
116	Management of antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 155-161.	0.9	85
117	Aspirin or heparin or both in the treatment of recurrent spontaneous abortion in women with antiphospholipid antibody syndrome: a meta-analysis of randomized controlled trials. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2019, 32, 1299-1311.	1.5	30
118	Newly Diagnosed Systemic Lupus Erythematosus. <i>Journal of Clinical Rheumatology</i> , 2019, 25, e109-e113.	0.9	1

#	ARTICLE	IF	CITATIONS
119	Successful treatment of catastrophic antiphospholipid syndrome with therapeutic plasma exchange: a case report. <i>Hematology, Transfusion and Cell Therapy</i> , 2020, 42, 287-291.	0.2	1
120	The pathogenic role of autoantibodies in recurrent pregnancy loss. <i>American Journal of Reproductive Immunology</i> , 2020, 83, e13200.	1.2	25
121	The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS. <i>Blood Reviews</i> , 2020, 39, 100610.	5.7	85
123	Antiphospholipid syndrome: Diagnosis and management in the obstetric patient. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2020, 64, 31-40.	2.8	18
124	Antiphospholipid syndrome. <i>Best Practice and Research in Clinical Rheumatology</i> , 2020, 34, 101463.	3.3	92
125	Serologically predicting direct oral anticoagulant failure with antiphospholipid antibodies. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 258-259.	3.8	0
126	Direct oral anticoagulants in antiphospholipid syndrome with venous thromboembolism: Impact of the European Medicines Agency guidance. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 9-12.	2.3	13
127	Antiphospholipid Syndrome: Therapeutic Challenges. <i>American Journal of Therapeutics</i> , 2020, 27, e328-e330.	0.9	0
128	Prevalence of confirmed antiphospholipid syndrome in 18-50 years unselected patients with first unprovoked venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 926-930.	3.8	29
129	Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome. <i>The Cochrane Library</i> , 2020, 10, CD012169.	2.8	18
130	Loss of antiphospholipid antibody positivity post-thrombosis in SLE. <i>Lupus Science and Medicine</i> , 2020, 7, e000423.	2.7	12
131	Functional lupus anticoagulant testing in a large retrospective cohort of thrombosis patients with direct oral anticoagulants. <i>Scientific Reports</i> , 2020, 10, 12221.	3.3	8
132	Ischemic stroke and cerebral venous sinus thrombosis in pregnancy. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2020, 172, 3-31.	1.8	17
133	Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2126-2137.	3.8	84
134	16th International Congress on Antiphospholipid Antibodies Task Force Report on Obstetric Antiphospholipid Syndrome. <i>Lupus</i> , 2020, 29, 1601-1615.	1.6	27
135	Antiphospholipid syndrome with chronic thromboembolic pulmonary hypertension and coronary artery disease: a case report. <i>Journal of Cardiothoracic Surgery</i> , 2020, 15, 225.	1.1	1
136	Ischemic Stroke in a Young Patient with Nephrotic Syndrome and Antiphospholipid Syndrome. <i>Case Reports in Nephrology</i> , 2020, 2020, 1-5.	0.4	1
137	Antiphospholipid syndrome and challenges with direct oral anticoagulants. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2020, 81, 1-11.	0.5	2

#	ARTICLE	IF	CITATIONS
138	Antiphospholipid syndrome. <i>Translational Research</i> , 2020, 225, 70-81.	5.0	44
139	Prevention of Pregnancy Complications in Antiphospholipid Syndrome. <i>Hamostaseologie</i> , 2020, 40, 174-183.	1.9	6
140	Foundation for Stroke in Systemic Sclerosis: A Clarion Call for Proactive Assessment?. <i>Journal of Rheumatology</i> , 2020, 47, 941.1-941.	2.0	3
141	Antiphospholipid Syndrome Is Still a Rare Diseaseâ€”Estimated Prevalence in the Piedmont and Aosta Valley Regions of Northwest Italy: Comment on the Article by Duarteâ€¢GarcÃa et al. <i>Arthritis and Rheumatology</i> , 2020, 72, 1774-1776.	5.6	12
142	Antiphospholipid antibodies in patients with dysglycaemia: A neglected cardiovascular risk factor?. <i>Diabetes and Vascular Disease Research</i> , 2020, 17, 147916412092212.	2.0	1
144	Seronegative antiphospholipid syndrome: refining the value of â€œnon-criteriaâ€•antibodies for diagnosis and clinical management. <i>Haematologica</i> , 2020, 105, 562-572.	3.5	81
145	Long term monitoring of patients with positive lupus anticoagulant and antiphospholipid antibodies. Are all cases persistently positive?. <i>Thrombosis Research</i> , 2020, 194, 119-120.	1.7	0
146	The prevalence of incidental uterine venous plexus thrombosis in women attending a gynecology clinic. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2557-2565.	3.8	8
147	What is the appropriate anticoagulation strategy for thrombotic antiphospholipid syndrome?. <i>British Journal of Haematology</i> , 2020, 189, 216-227.	2.5	14
148	Addendum to British Society for Haematology Guidelines on Investigation and Management of Antiphospholipid syndrome, 2012 (<i>Br. J. Haematol</i> 2012; 157: 47â€“58): use of direct acting oral anticoagulants. <i>British Journal of Haematology</i> , 2020, 189, 212-215.	2.5	53
149	The antiphospholipid syndrome â€œ often overlooked cause of vascular occlusions?. <i>Journal of Internal Medicine</i> , 2020, 287, 349-372.	6.0	27
150	Systematic review of observational studies reporting antiphospholipid antibodies in patients with solid tumors. <i>Blood Advances</i> , 2020, 4, 1746-1755.	5.2	17
151	Treatment of thrombotic antiphospholipid syndrome in adults and children. <i>Current Opinion in Rheumatology</i> , 2020, 32, 215-227.	4.3	8
152	Thrombotic antiphospholipid syndrome: A practical guide to diagnosis and management. <i>Thrombosis Research</i> , 2021, 198, 213-221.	1.7	39
153	Arterial thrombosis in antiphospholipid syndrome (APS): Clinical approach and treatment. A systematic review. <i>Blood Reviews</i> , 2021, 48, 100788.	5.7	16
154	Primary antiphospholipid syndrome revealed by acute myocardial infarction in young adults: a prospective observational study. <i>Thrombosis Research</i> , 2021, 198, 151-153.	1.7	1
155	Monitoring of anticoagulation in thrombotic antiphospholipid syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 892-908.	3.8	20
156	Clinical presentation of antiphospholipid syndrome. , 2021, , 561-574.		0

#	ARTICLE	IF	CITATIONS
157	Antiphospholipid Syndrome in a Patient with Systemic Lupus Erythematosus Elements. , 2021, , 79-86.		0
158	Prognostic analysis of antibody typing and treatment for antiphospholipid syndromeâ€related recurrent spontaneous abortion. International Journal of Gynecology and Obstetrics, 2022, 156, 107-111.	2.3	3
159	Comparison of patients with transient and sustained increments of antiphospholipid antibodies after acute ischemic stroke. Journal of Neurology, 2021, 268, 2541-2549.	3.6	1
160	Risk factors for ischemic antiphospholipid syndrome: A case-control study. Clinical Neurology and Neurosurgery, 2021, 202, 106492.	1.4	4
161	Current concepts in the diagnosis and management of antiphospholipid syndrome and ocular manifestations. Journal of Ophthalmic Inflammation and Infection, 2021, 11, 11.	2.2	14
162	Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update. Current Rheumatology Reports, 2021, 23, 45.	4.7	9
163	The neurology of lupus. Journal of the Neurological Sciences, 2021, 424, 117419.	0.6	7
164	New insights into the pathogenic mechanisms and treatment of arterial thrombosis in antiphospholipid syndrome. European Journal of Rheumatology, 2021, 8, 93-99.	0.6	6
165	Presence of Extra-Criteria Antiphospholipid Antibodies Is an Independent Risk Factor for Ischemic Stroke. Frontiers in Cardiovascular Medicine, 2021, 8, 665741.	2.4	14
166	Arterial Dissection in Antiphospholipid Syndrome Patients: Two Case Reports and a Literature Review. European Journal of Case Reports in Internal Medicine, 2021, 8, 002610.	0.4	2
167	Antiphospholipid antibodies levels and potential effects on in-vitro fertilization in a large cohort of infertile Syrian women. Annals of Medicine and Surgery, 2021, 65, 102301.	1.1	3
168	Antiphospholipid antibodies quantification using ALBIA technology: how to define an optimal cutoff?. Clinical Chemistry and Laboratory Medicine, 2021, 59, e454-e457.	2.3	1
169	Small Bowel Necrosis Associated with Catastrophic Antiphospholipid Syndrome: A Case Report. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2021, 77, 294-299.	0.4	1
170	Reducing the diagnostic delay in Antiphospholipid Syndrome over time: a real world observation. Orphanet Journal of Rare Diseases, 2021, 16, 280.	2.7	8
171	Neurologic Manifestations of the Antiphospholipid Syndrome â€” an Update. Current Neurology and Neuroscience Reports, 2021, 21, 41.	4.2	26
172	The antiphospholipid syndrome. Revista Colombiana De ReumatologÃa, 2021, 28, 166-176.	0.1	0
173	Direct oral anticoagulants versus vitamin K antagonists in patients with antiphospholipid syndrome: systematic review and meta-analysis. RMD Open, 2021, 7, e001678.	3.8	12
174	Cerebrovascular events in patients with isolated anti-phosphatidyl-serine/prothrombin antibodies. Immunologic Research, 2021, 69, 372-377.	2.9	4

#	ARTICLE	IF	CITATIONS
175	2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. <i>Stroke</i> , 2021, 52, e364-e467.	2.0	1,123
176	Evaluation and management of patients with chronic thromboembolic pulmonary hypertension - consensus statement from the ISHLT. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 1301-1326.	0.6	36
177	Placental contribution to neonatal encephalopathy. <i>Seminars in Fetal and Neonatal Medicine</i> , 2021, 26, 101276.	2.3	13
178	Obstetric anti-phospholipid syndrome: from pathogenesis to treatment. <i>Immunological Medicine</i> , 2022, 45, 79-93.	2.6	8
179	Correlation Analysis of Anti-Cardiolipin Antibody/D Dimer/C-Reactive Protein and Coronary Artery Lesions/Multiple-Organ Damage in Children With Kawasaki Disease. <i>Frontiers in Pediatrics</i> , 2021, 9, 704929.	1.9	3
180	Development of multifocal ischemic stroke after cessation of anticoagulant therapy in a patient with antiphospholipid syndrome. <i>Science and Innovations in Medicine</i> , 2021, 6, 42-45.	0.1	0
181	Protein Phosphatase 2A Activation Via ApoER2 in Trophoblasts Drives Preeclampsia in a Mouse Model of the Antiphospholipid Syndrome. <i>Circulation Research</i> , 2021, 129, 735-750.	4.5	10
182	Evaluation of the Diagnostic Value of Non-criteria Antibodies for Antiphospholipid Syndrome Patients in a Chinese Cohort. <i>Frontiers in Immunology</i> , 2021, 12, 741369.	4.8	10
183	Hematologic Disorders and Stroke. , 2022, , 592-603.e6.		0
184	BACTERIAL INFECTION CAUSES OF PREGNANCY LOSS AND PREMATURE BIRTH IN THE WOMEN IN UKRAINE. <i>Wiadomości Lekarskie</i> , 2021, 74, 1355-1359.	0.3	8
185	Neuropsychiatric Manifestations of Antiphospholipid Syndrome. , 2017, , 201-219.		2
186	15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Classification Report. , 2017, , 279-290.		4
187	Mechanisms of Antiphospholipid Antibody-Mediated Thrombosis. , 2017, , 77-116.		3
188	Antiphospholipid syndrome – an update. <i>Vasa - European Journal of Vascular Medicine</i> , 2018, 47, 451-464.	1.4	58
189	Cardiovascular Disease in Antiphospholipid Syndrome. <i>Current Vascular Pharmacology</i> , 2020, 18, 538-548.	1.7	6
190	Laboratory tests in rheumatology: A rational approach. <i>Cleveland Clinic Journal of Medicine</i> , 2019, 86, 198-210.	1.3	6
191	Infodemiology of antiphospholipid syndrome: Merging informatics and epidemiology. <i>European Journal of Rheumatology</i> , 2018, 5, 92-95.	0.6	14
192	Comparison of the Therapeutic Effects of Rivaroxaban Versus Warfarin in Antiphospholipid Syndrome: A Systematic Review. <i>Archives of Rheumatology</i> , 2020, 35, 107-116.	0.9	4

#	ARTICLE	IF	CITATIONS
193	OUP accepted manuscript. journal of applied laboratory medicine, The, 2022, 7, 373-378.	1.3	0
194	Role of Direct Oral Anticoagulation Agents as Thromboprophylaxis in Antiphospholipid Syndrome. Cureus, 2021, 13, e19009.	0.5	3
195	Diagnosis and management of obstetrical antiphospholipid syndrome: where do we stand?. Polish Archives of Internal Medicine, 2013, 123, 713-720.	0.4	2
198	Systemic Thromboembolism in Pregnancy: Cerebrovascular Disease. , 2015, , 105-124.		0
199	Obstetrical Considerations and Management of Antiphospholipid Syndrome. The Open Urology & Nephrology Journal, 2015, 8, 22-26.	0.2	0
200	Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION). , 2017, , 267-276.		1
201	Definition and Epidemiology of Antiphospholipid Syndrome. , 2017, , 147-169.		1
202	Antiphospholipid Syndrome: What Should Patients Know?. , 2017, , 341-357.		1
204	SÃndrome antifosfolipÃdico. EMC - Aparato Locomotor, 2019, 52, 1-16.	0.1	0
205	Impact of antiphospholipid syndrome iBook on medical studentsâ™ improvement of knowledge: An international randomized controlled study. European Journal of Rheumatology, 2019, 6, 207-211.	0.6	1
206	Pulmonary involvement in antiphospholipid syndrome. , 2019, , 124-139.		0
207	A Male Case of Primary Antiphospholipid Syndrome and Recurrent Deep Venous Thrombosis. Journal of Exploratory Research in Pharmacology, 2020, 000, 1-5.	0.4	0
208	Thrombotic risk assessment in patients with systemic lupus erythematosus: Validation of the adjustedâ€Global Antiphospholipid Syndrome Score (aGAPSS) in Thai patients. International Journal of Rheumatic Diseases, 2021, 24, 1510-1519.	1.9	2
209	Proteomics and enriched biological processes in Antiphospholipid syndrome: A systematic review. Autoimmunity Reviews, 2021, 20, 102982.	5.8	4
210	Fetal Loss. , 2022, , 187-215.		0
211	Update on Use of Biologic and Targeted Synthetic Drugs in Pregnancy. , 2020, , 77-92.		1
213	Antiphospholipid Antibodies From Women With Pregnancy Morbidity and Vascular Thrombosis Induce Endothelial Mitochondrial Dysfunction, mTOR Activation, and Autophagy. Frontiers in Physiology, 2021, 12, 706743.	2.8	11
214	Indication and outcome of lupus anticoagulant and antiphospholipid antibodies testing in routine clinical practice. Rheumatology Advances in Practice, 2021, 5, rkab093.	0.7	1

#	ARTICLE	IF	CITATIONS
215	Antiphospholipid antibodies in patients with myocardial infarction with and without obstructive coronary arteries. <i>Journal of Internal Medicine</i> , 2022, 291, 327-337.	6.0	3
217	Clinical Management of Thrombotic Antiphospholipid Syndrome. <i>Journal of Clinical Medicine</i> , 2022, 11, 735.	2.4	11
218	Pathogenesis, Diagnosis and Management of Obstetric Antiphospholipid Syndrome: A Comprehensive Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 675.	2.4	33
219	Obstetric Antiphospholipid Syndrome From the Perspective of a Rheumatologist. <i>Cureus</i> , 2022, 14, e21090.	0.5	3
220	Detection of IgA Antiphospholipid Antibodies Does not Improve Thrombotic Antiphospholipid Syndrome Classification: A two-Center Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962210811.	1.7	3
221	Obstetric Antiphospholipid Syndrome. , 0, , .		0
222	Risk of Thrombosis, Pregnancy Morbidity or Death in Antiphospholipid Syndrome. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 852777.	2.4	8
223	Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management. <i>Autoimmunity Reviews</i> , 2022, 21, 103072.	5.8	10
224	Epidemiology of Antiphospholipid Syndrome in the General Population. <i>Current Rheumatology Reports</i> , 2021, 23, 85.	4.7	49
225	Antiphospholipid Syndrome and Stroke. , 0, , .		0
228	A Young Man with Transient Visual Loss and Recurrent Myocardial Infarction: A Case Report. <i>Acta Cardiologica Sinica</i> , 2021, 37, 664-667.	0.2	0
230	Introductory Chapter: Antiphospholipid Antibodies - A Laboratory Criterion for the Antiphospholipid Syndrome, but Also Bystanders in Infections, Cancer, and Other Conditions. , 0, , .		0
231	Collagen Vascular Diseases in Pregnancy. , 2017, , 981-997.		0
232	Pregnancy-Related Stroke: A Review. <i>Obstetrical and Gynecological Survey</i> , 2022, 77, 367-378.	0.4	0
233	What are the prospects for antiplatelet agents for thromboprophylaxis in antiphospholipid syndrome?. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 779-781.	3.0	1
234	Analysis of Serbian Primary Antiphospholipid Syndrome Patients Confirmed a Strong Association Between Livedo Reticularis and Arterial Thrombosis. <i>Journal of Clinical Rheumatology</i> , 0, Publish Ahead of Print, .	0.9	0
235	Antiphospholipid Syndrome in Patients with Venous Thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 833-839.	2.7	3
236	Antiphospholipid syndrome and recurrent pregnancy losses. , 2022, , 121-136.		0

#	ARTICLE	IF	CITATIONS
237	Risk Factors and Outcomes of Acute Myocardial Infarction in a Cohort of Antiphospholipid Syndrome. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	2
238	Pathophysiology of Placenta in Antiphospholipid Syndrome. <i>Physiologia</i> , 2022, 2, 66-79.	2.2	0
239	Left ventricular size and function in patients with systemic lupus erythematosus associate with lupus anticoagulant: An echocardiographic follow-up study. <i>Journal of Autoimmunity</i> , 2022, 132, 102884.	6.5	2
240	Frequency of positive antiphospholipid antibodies in pregnant women with SARS-CoV-2 infection and impact on pregnancy outcome: A single-center prospective study on 151 pregnancies. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	1
241	Paciente joven con accidente cerebrovascular isqu�mico: �Se debe buscar una trombofilia?. <i>Revista M�dica De Risaralda</i> , 2022, 28, .	0.1	1
242	Acute Coronary Syndromes in Antiphospholipid Syndrome-above Suspicion: A Systematic Review. <i>Current Problems in Cardiology</i> , 2023, 48, 101503.	2.4	1
243	Update on the Diagnosis and Anticoagulant Treatment of the Antiphospholipid Syndrome. <i>European Medical Journal Rheumatology</i> , 0, , 101-111.	0.0	3
244	Rheumatologische Krankheiten und Schwangerschaft: Systemischer Lupus erythematoses, Antiphospholipidsyndrom, rheumatoide Arthritis, Spondyloarthritis, systemische Sklerose, entz�ndliche Myopathien und Vaskulitis. <i>Springer Reference Medizin</i> , 2022, , 1-20.	0.0	0
245	Evolution of Antiphospholipid Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 295-304.	2.7	4
246	Antiphospholipid antibodies in pulmonary embolism treated with direct oral anticoagulants: Prevalence data from unselected consecutive patients. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2023, , 100050.	2.3	0
247	Recent and ongoing technological advancements in forensic pathology practice. , 2023, , 527-537.		0
248	Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management. <i>BMJ, The</i> , 0, , e069717.	6.0	33
249	Incidence of Antiphospholipid Syndrome: Is Estimation Currently Possible?. , 2023, 10, 39-44.		2
250	Pediatric Presentation of Antiphospholipid Syndrome: A Review of Recent Literature With Estimation of Local Prevalence. <i>Seminars in Thrombosis and Hemostasis</i> , 2024, 50, 182-187.	2.7	0
251	Thrombotic Antiphospholipid Syndrome and Direct Oral Anticoagulants: Unmet Needs and Review of the Literature. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 736-743.	2.7	2
252	Clinical lesson to not overlook venous thrombosis: a case of primary antiphospholipid syndrome. <i>BMJ Case Reports</i> , 2023, 16, e254671.	0.5	0
253	Profile and clinical relevance of non-criteria antiphospholipid antibodies in patients diagnosed with or highly suspected of APS. <i>Rheumatology</i> , 2024, 63, 891-900.	1.9	1
254	First-trimester serum antiphosphatidylserine antibodies serve as candidate biomarkers for predicting pregnancy-induced hypertension. <i>Journal of Hypertension</i> , 0, Publish Ahead of Print, .	0.5	0

#	ARTICLE	IF	CITATIONS
255	Management of Postpartum Extensive Venous Thrombosis after Second Pregnancy. <i>Medicina (Lithuania)</i> , 2023, 59, 871.	2.0	0
256	Positive antiphospholipid antibodies: observation or treatment?. <i>Journal of Thrombosis and Thrombolysis</i> , 2023, 56, 301-314.	2.1	2
257	Survey on antiphospholipid syndrome diagnosis and antithrombotic treatment in patients with ischemic stroke, other brain ischemic injury, or arterial thromboembolism in other sites: communication from ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 2963-2976.	3.8	2
258	Oligosymptomatic infection by SARS-Cov-2 in catastrophic antiphospholipid syndrome, a singular coincidence: a case report in an Ecuadorian hospital. <i>Hematology, Transfusion and Cell Therapy</i> , 2023, , .	0.2	0
259	Anti-Phospholipid Antibodies in Women with Placenta-Mediated Complications Delivered at >34 Weeks of Gestation. <i>Journal of Clinical Medicine</i> , 2023, 12, 4516.	2.4	0
260	Catastrophic antiphospholipid syndrome: current aspects of pathogenesis, diagnosis and treatment. <i>Sovremennaya Revmatologiya</i> , 2023, 17, 7-15.	0.5	0
261	Modulation of the activation of endothelial nitric oxide synthase and nitrosative stress biomarkers by aspirin triggered lipoxins: A possible mechanism of action of aspirin in the antiphospholipid syndrome. <i>American Journal of Reproductive Immunology</i> , 2023, 90, .	1.2	0
262	Anti-thrombotics and major adverse cardiovascular events in anti-phospholipid syndrome: a cross-sectional study using the 2016-2018 National Inpatient Sample database. <i>Scandinavian Journal of Rheumatology</i> , 0, , 1-7.	1.1	0
263	Preeclampsia and the Antiphospholipid Syndrome. <i>Biomedicines</i> , 2023, 11, 2298.	3.2	1
264	Trophoblast Cell Function in the Antiphospholipid Syndrome. <i>Biomedicines</i> , 2023, 11, 2681.	3.2	1
265	Antiphospholipid syndrome in cardiovascular disease and cancer. <i>European Journal of Haematology</i> , 2023, 111, 834-843.	2.2	1
266	Antiphospholipid syndrome and kidney involvement. <i>Kidney and Blood Pressure Research</i> , 0, , .	2.0	0
267	Emboic Phenomena of Libman-Sacks Endocarditis and Antiphospholipid Syndrome. <i>Cureus</i> , 2023, , .	0.5	0
268	The estimated prevalence of antiphospholipid antibodies and criteria-antiphospholipid syndrome in subjects with renal thrombotic microangiopathy. <i>Lupus</i> , 0, , .	1.6	0
269	Coronary Thrombosis with Distal Embolization in a Young Patient after Orthopaedic Surgery: An Informative Case Report. <i>Seminars in Thrombosis and Hemostasis</i> , 0, , .	2.7	0
270	How I diagnose and treat antiphospholipid syndrome in pregnancy. <i>Blood</i> , 2024, 143, 757-768.	1.4	0
271	Thrombophilia Testing in Stroke: A Case Report and Review of Evidence. <i>Cureus</i> , 2023, , .	0.5	0
272	Evaluation of Recurrent Pregnancy Loss. <i>Obstetrics and Gynecology</i> , 2024, 143, 645-659.	2.4	0

#	ARTICLE	IF	CITATIONS
273	Spontaneous coronary artery dissection in a young patient with antiphospholipid syndrome. <i>Thrombosis Journal</i> , 2024, 22, .	2.1	0
274	The prevalence and incidence of thrombotic primary antiphospholipid syndrome in adults aged 18–49 years: A population-based study in a mountain community in northern Italy. <i>Clinical Immunology</i> , 2024, 260, 109905.	3.2	0
275	Epidemiology of antiphospholipid syndrome: macro- and microvascular manifestations. <i>Rheumatology</i> , 2024, 63, S124-S136.	1.9	1